Fredun Pharmaceuticals Ltd
BSE:539730

Watchlist Manager
Fredun Pharmaceuticals Ltd Logo
Fredun Pharmaceuticals Ltd
BSE:539730
Watchlist
Price: 1 479.05 INR -2.1%
Market Cap: 7B INR
Section:
 

Relative Value

The Relative Value of one FREDUN stock under the Base Case scenario is hidden INR. Compared to the current market price of 1 479.05 INR, Fredun Pharmaceuticals Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FREDUN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.4
P/S
P/S
Price to Sales
1.4
vs History
38
vs Industry
73
Median 3Y
1.3
Median 5Y
1.3
Industry
2.6
More Details
31.2
P/E
P/E
Price to Earnings
31.2
vs History
60
vs Industry
27
Median 3Y
28.1
Median 5Y
36.7
Industry
21.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
42
Median 3Y
-19.1
Median 5Y
-16.3
Industry
16.4
More Details
67.6
P/FCFE
P/FCFE
Price to FCFE
67.6
vs History
50
vs Industry
1
Median 3Y
61.1
Median 5Y
70.3
Industry
22.8
More Details
4.9
P/B
P/B
Price to Book Value
4.9
vs History
31
vs Industry
29
Median 3Y
3.6
Median 5Y
3.9
Industry
2.2
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
50
vs Industry
75
Median 3Y
1.3
Median 5Y
1.5
Industry
2.9
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
65
vs Industry
53
Median 3Y
5.9
Median 5Y
7
Industry
5.5
More Details
12
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12
vs History
61
vs Industry
40
Median 3Y
11.1
Median 5Y
15.6
Industry
13
More Details
13.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.1
vs History
61
vs Industry
41
Median 3Y
12.4
Median 5Y
17.9
Industry
16.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
41
Median 3Y
-21
Median 5Y
-16.4
Industry
15.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
30
Median 3Y
-15.9
Median 5Y
-17.7
Industry
18.7
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
53
vs Industry
51
Median 3Y
2
Median 5Y
2.2
Industry
1.9
More Details

Multiples Across Competitors

FREDUN Competitors Multiples
Fredun Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Fredun Pharmaceuticals Ltd
BSE:539730
7B INR 1.4 31.2 12 13.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.7 37.4 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
495.1B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
270.3B CHF 4.4 28.7 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
219.8B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276.1B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
218.3B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.8B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Fredun Pharmaceuticals Ltd
BSE:539730
Average P/E: 25.6
31.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Fredun Pharmaceuticals Ltd
BSE:539730
Average EV/EBITDA: 401.1
12
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Fredun Pharmaceuticals Ltd
BSE:539730
Average EV/EBIT: 1 713.6
13.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
FREDUN intrinsic value, competitors valuation, and company profile.
DCF Valuation
FREDUN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FREDUN stock valuation using valuation multiples.
Wall Street Estimates
FREDUN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FREDUN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.